DOCSLIB.ORG

Capturing Epigenomes at High-Resolution for Insight Into Genome Function and Metabolic Disease Risk

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Capturing Epigenomes at High-Resolution for Insight Into Genome Function and Metabolic Disease Risk Capturing epigenomes at high-resolution for insight into genome function and metabolic disease risk Fiona Allum Department of Human Genetics Faculty of Medicine McGill University, Montréal April 2019 A thesis submitted to McGill University in partial fulfillment of the requirements of the degree of Doctor of Philosophy © Fiona Allum 2019 “It does not do to dwell on dreams and forget to live” - Albus Dumbledore (J.K. Rowling) 2 Table of Contents ABSTRACT ..................................................................................................................... 6 RÉSUMÉ ......................................................................................................................... 8 LIST OF ABBREVIATIONS ......................................................................................... 10 LIST OF TABLES ......................................................................................................... 15 LIST OF FIGURES ....................................................................................................... 16 ACKNOWLEDGMENTS .............................................................................................. 18 PREFACE ...................................................................................................................... 20 Format of the Thesis ................................................................................................................. 20 Contribution of Authors ............................................................................................................ 21 Original Contribution to Knowledge ........................................................................................ 23 CHAPTER 1: INTRODUCTION .................................................................................. 26 1.1 Studying Complex Traits: Focus on Metabolic Diseases .................................................. 26 1.1.1 Pathophysiology and Socioeconomic Burden ......................................................................... 26 1.1.2 Environmental and Genetic Factors Contributing to Disease .............................................. 27 1.2 Genome-wide Association Studies ..................................................................................... 28 1.2.1 GWAS of BMI, fat distribution and lipids .............................................................................. 28 1.2.2 Limitations of GWAS ............................................................................................................... 29 1.2.3 Missing Heritability in Common Diseases ............................................................................. 30 1.2.4 Integrational Studies to Interpret Genetic Variants ............................................................. 31 1.2.5 Expression Quantitative Trait Loci Studies .......................................................................... 32 1.3 Epigenetics to Link Environment and Genetics to Disease Phenotypes ......................... 33 1.3.1 What is Epigenetics? ............................................................................................................... 33 1.3.2 Reference Epigenome Efforts .................................................................................................. 34 1.3.3 Defining Regulatory Elements ................................................................................................ 35 1.3.4 Coordinated Patterns of Epigenetic Regulation ..................................................................... 38 1.4 DNA methylation ................................................................................................................ 39 1.4.1 Roles of DNA Methylation across the Genome ...................................................................... 40 1.4.2 Methods to Study DNA Methylation ...................................................................................... 41 1.4.3 Epigenome-wide Association Studies of Common Traits ...................................................... 42 1.5 Rationale, Hypothesis and Objectives ............................................................................... 45 CHAPTER 2: CHARACTERIZATION OF METHYLOMES BY NEXT-GENERATION CAPTURE SEQUENCING .......................................................................................... 48 2.1 Bridging Statement between Chapter 1 and 2 .................................................................. 48 2.2 Title, Authors and Affiliations ........................................................................................... 50 3 2.3 Abstract ............................................................................................................................... 53 2.4 Introduction ......................................................................................................................... 54 2.5 Results ................................................................................................................................. 58 2.5.1 First-generation Capture Panel Design for MCC-Seq ........................................................... 58 2.5.2 Second-generation Panel Design for Comprehensive Profiling ............................................. 59 2.5.3 Sample-based Validation of MCC-Seq .................................................................................... 60 2.5.4 Population-based Validation of MCC-Seq .............................................................................. 62 2.5.5 Population-based Genotype Profiling by MCC-Seq ............................................................... 65 2.5.6 EWAS of TG Levels using MCC-Seq ...................................................................................... 66 2.5.7 Assessment of Loci Harbouring TG-associated CpGs ............................................................ 68 2.5.8 Follow-up of the TG-associated Loci Mapping to CD36 ......................................................... 70 2.6 Discussion ............................................................................................................................ 72 2.7 Online Methods ................................................................................................................... 76 2.7.1 First-generation Panel Design ................................................................................................ 76 2.7.2 Generation of Second-general Panel ....................................................................................... 78 2.7.3 MCC-Seq Protocol .................................................................................................................... 79 2.7.4 MCC-Seq Methylation Profiling .............................................................................................. 80 2.7.5 Illumina 450K Array Methylation Profiling .......................................................................... 81 2.7.6 Agilent SureSelect CpG Profiling and MCC-Seq Comparisons ............................................ 82 2.7.7 Trait-association Discovery Cohort ......................................................................................... 83 2.7.8 DNA Isolation ........................................................................................................................... 84 2.7.9 Identification of Hypomethylated Regions ............................................................................. 84 2.7.10 Genotyping ............................................................................................................................. 85 2.7.11 Epigenome-wide Association of TG Levels ........................................................................... 86 2.7.12 Adipocyte Nuclei Isolation ..................................................................................................... 87 2.7.13 Transposase-accessible chromatin Sequencing .................................................................... 87 2.7.14 Blood Cell Isolation ................................................................................................................ 88 2.7.15 RNA Sequencing .................................................................................................................... 89 2.8 Acknowledgements .............................................................................................................. 90 2.9 Additional Information ....................................................................................................... 92 Accession codes ................................................................................................................................. 92 Competing financial interests .......................................................................................................... 92 The Multiple Tissue Human Expression Resource Consortium .................................................... 93 2.10 Main Tables and Figures .................................................................................................. 94 2.10.1 Tables ...................................................................................................................................... 94 2.10.2 Figures .................................................................................................................................... 95 2.11 Supplementary Materials ............................................................................................... 100 2.11.1 Supplementary Tables ........................................................................................................
Load more

Recommended publications
  • Dual Proteome-Scale Networks Reveal Cell-Specific Remodeling of the Human Interactome
    bioRxiv preprint doi: https://doi.org/10.1101/2020.01.19.905109; this version posted January 19, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission. Dual Proteome-scale Networks Reveal Cell-specific Remodeling of the Human Interactome Edward L. Huttlin1*, Raphael J. Bruckner1,3, Jose Navarrete-Perea1, Joe R. Cannon1,4, Kurt Baltier1,5, Fana Gebreab1, Melanie P. Gygi1, Alexandra Thornock1, Gabriela Zarraga1,6, Stanley Tam1,7, John Szpyt1, Alexandra Panov1, Hannah Parzen1,8, Sipei Fu1, Arvene Golbazi1, Eila Maenpaa1, Keegan Stricker1, Sanjukta Guha Thakurta1, Ramin Rad1, Joshua Pan2, David P. Nusinow1, Joao A. Paulo1, Devin K. Schweppe1, Laura Pontano Vaites1, J. Wade Harper1*, Steven P. Gygi1*# 1Department of Cell Biology, Harvard Medical School, Boston, MA, 02115, USA. 2Broad Institute, Cambridge, MA, 02142, USA. 3Present address: ICCB-Longwood Screening Facility, Harvard Medical School, Boston, MA, 02115, USA. 4Present address: Merck, West Point, PA, 19486, USA. 5Present address: IQ Proteomics, Cambridge, MA, 02139, USA. 6Present address: Vor Biopharma, Cambridge, MA, 02142, USA. 7Present address: Rubius Therapeutics, Cambridge, MA, 02139, USA. 8Present address: RPS North America, South Kingstown, RI, 02879, USA. *Correspondence: [email protected] (E.L.H.), [email protected] (J.W.H.), [email protected] (S.P.G.) #Lead Contact: [email protected] bioRxiv preprint doi: https://doi.org/10.1101/2020.01.19.905109; this version posted January 19, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder.
    [Show full text]
  • A Computational Approach for Defining a Signature of Β-Cell Golgi Stress in Diabetes Mellitus
    Page 1 of 781 Diabetes A Computational Approach for Defining a Signature of β-Cell Golgi Stress in Diabetes Mellitus Robert N. Bone1,6,7, Olufunmilola Oyebamiji2, Sayali Talware2, Sharmila Selvaraj2, Preethi Krishnan3,6, Farooq Syed1,6,7, Huanmei Wu2, Carmella Evans-Molina 1,3,4,5,6,7,8* Departments of 1Pediatrics, 3Medicine, 4Anatomy, Cell Biology & Physiology, 5Biochemistry & Molecular Biology, the 6Center for Diabetes & Metabolic Diseases, and the 7Herman B. Wells Center for Pediatric Research, Indiana University School of Medicine, Indianapolis, IN 46202; 2Department of BioHealth Informatics, Indiana University-Purdue University Indianapolis, Indianapolis, IN, 46202; 8Roudebush VA Medical Center, Indianapolis, IN 46202. *Corresponding Author(s): Carmella Evans-Molina, MD, PhD ([email protected]) Indiana University School of Medicine, 635 Barnhill Drive, MS 2031A, Indianapolis, IN 46202, Telephone: (317) 274-4145, Fax (317) 274-4107 Running Title: Golgi Stress Response in Diabetes Word Count: 4358 Number of Figures: 6 Keywords: Golgi apparatus stress, Islets, β cell, Type 1 diabetes, Type 2 diabetes 1 Diabetes Publish Ahead of Print, published online August 20, 2020 Diabetes Page 2 of 781 ABSTRACT The Golgi apparatus (GA) is an important site of insulin processing and granule maturation, but whether GA organelle dysfunction and GA stress are present in the diabetic β-cell has not been tested. We utilized an informatics-based approach to develop a transcriptional signature of β-cell GA stress using existing RNA sequencing and microarray datasets generated using human islets from donors with diabetes and islets where type 1(T1D) and type 2 diabetes (T2D) had been modeled ex vivo. To narrow our results to GA-specific genes, we applied a filter set of 1,030 genes accepted as GA associated.
    [Show full text]
  • PRODUCT SPECIFICATION Prest Antigen C19orf25 Product
    PrEST Antigen C19orf25 Product Datasheet PrEST Antigen PRODUCT SPECIFICATION Product Name PrEST Antigen C19orf25 Product Number APrEST85422 Gene Description chromosome 19 open reading frame 25 Alternative Gene FLJ36666 Names Corresponding Anti-C19orf25 (HPA050270) Antibodies Description Recombinant protein fragment of Human C19orf25 Amino Acid Sequence Recombinant Protein Epitope Signature Tag (PrEST) antigen sequence: GEQLYQQSRAYVAANQRLQQAGNVLRQRCELLQRAGEDLEREVAQMKQAA LPAAEAASSG Fusion Tag N-terminal His6ABP (ABP = Albumin Binding Protein derived from Streptococcal Protein G) Expression Host E. coli Purification IMAC purification Predicted MW 24 kDa including tags Usage Suitable as control in WB and preadsorption assays using indicated corresponding antibodies. Purity >80% by SDS-PAGE and Coomassie blue staining Buffer PBS and 1M Urea, pH 7.4. Unit Size 100 µl Concentration Lot dependent Storage Upon delivery store at -20°C. Avoid repeated freeze/thaw cycles. Notes Gently mix before use. Optimal concentrations and conditions for each application should be determined by the user. Product of Sweden. For research use only. Not intended for pharmaceutical development, diagnostic, therapeutic or any in vivo use. No products from Atlas Antibodies may be resold, modified for resale or used to manufacture commercial products without prior written approval from Atlas Antibodies AB. Warranty: The products supplied by Atlas Antibodies are warranted to meet stated product specifications and to conform to label descriptions when used and stored properly. Unless otherwise stated, this warranty is limited to one year from date of sales for products used, handled and stored according to Atlas Antibodies AB's instructions. Atlas Antibodies AB's sole liability is limited to replacement of the product or refund of the purchase price.
    [Show full text]
  • Literature Mining Sustains and Enhances Knowledge Discovery from Omic Studies
    LITERATURE MINING SUSTAINS AND ENHANCES KNOWLEDGE DISCOVERY FROM OMIC STUDIES by Rick Matthew Jordan B.S. Biology, University of Pittsburgh, 1996 M.S. Molecular Biology/Biotechnology, East Carolina University, 2001 M.S. Biomedical Informatics, University of Pittsburgh, 2005 Submitted to the Graduate Faculty of School of Medicine in partial fulfillment of the requirements for the degree of Doctor of Philosophy University of Pittsburgh 2016 UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE This dissertation was presented by Rick Matthew Jordan It was defended on December 2, 2015 and approved by Shyam Visweswaran, M.D., Ph.D., Associate Professor Rebecca Jacobson, M.D., M.S., Professor Songjian Lu, Ph.D., Assistant Professor Dissertation Advisor: Vanathi Gopalakrishnan, Ph.D., Associate Professor ii Copyright © by Rick Matthew Jordan 2016 iii LITERATURE MINING SUSTAINS AND ENHANCES KNOWLEDGE DISCOVERY FROM OMIC STUDIES Rick Matthew Jordan, M.S. University of Pittsburgh, 2016 Genomic, proteomic and other experimentally generated data from studies of biological systems aiming to discover disease biomarkers are currently analyzed without sufficient supporting evidence from the literature due to complexities associated with automated processing. Extracting prior knowledge about markers associated with biological sample types and disease states from the literature is tedious, and little research has been performed to understand how to use this knowledge to inform the generation of classification models from ‘omic’ data. Using pathway analysis methods to better understand the underlying biology of complex diseases such as breast and lung cancers is state-of-the-art. However, the problem of how to combine literature- mining evidence with pathway analysis evidence is an open problem in biomedical informatics research.
    [Show full text]
  • Appendix 2. Significantly Differentially Regulated Genes in Term Compared with Second Trimester Amniotic Fluid Supernatant
    Appendix 2. Significantly Differentially Regulated Genes in Term Compared With Second Trimester Amniotic Fluid Supernatant Fold Change in term vs second trimester Amniotic Affymetrix Duplicate Fluid Probe ID probes Symbol Entrez Gene Name 1019.9 217059_at D MUC7 mucin 7, secreted 424.5 211735_x_at D SFTPC surfactant protein C 416.2 206835_at STATH statherin 363.4 214387_x_at D SFTPC surfactant protein C 295.5 205982_x_at D SFTPC surfactant protein C 288.7 1553454_at RPTN repetin solute carrier family 34 (sodium 251.3 204124_at SLC34A2 phosphate), member 2 238.9 206786_at HTN3 histatin 3 161.5 220191_at GKN1 gastrokine 1 152.7 223678_s_at D SFTPA2 surfactant protein A2 130.9 207430_s_at D MSMB microseminoprotein, beta- 99.0 214199_at SFTPD surfactant protein D major histocompatibility complex, class II, 96.5 210982_s_at D HLA-DRA DR alpha 96.5 221133_s_at D CLDN18 claudin 18 94.4 238222_at GKN2 gastrokine 2 93.7 1557961_s_at D LOC100127983 uncharacterized LOC100127983 93.1 229584_at LRRK2 leucine-rich repeat kinase 2 HOXD cluster antisense RNA 1 (non- 88.6 242042_s_at D HOXD-AS1 protein coding) 86.0 205569_at LAMP3 lysosomal-associated membrane protein 3 85.4 232698_at BPIFB2 BPI fold containing family B, member 2 84.4 205979_at SCGB2A1 secretoglobin, family 2A, member 1 84.3 230469_at RTKN2 rhotekin 2 82.2 204130_at HSD11B2 hydroxysteroid (11-beta) dehydrogenase 2 81.9 222242_s_at KLK5 kallikrein-related peptidase 5 77.0 237281_at AKAP14 A kinase (PRKA) anchor protein 14 76.7 1553602_at MUCL1 mucin-like 1 76.3 216359_at D MUC7 mucin 7,
    [Show full text]
  • WO 2012/174282 A2 20 December 2012 (20.12.2012) P O P C T
    (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (10) International Publication Number (43) International Publication Date WO 2012/174282 A2 20 December 2012 (20.12.2012) P O P C T (51) International Patent Classification: David [US/US]; 13539 N . 95th Way, Scottsdale, AZ C12Q 1/68 (2006.01) 85260 (US). (21) International Application Number: (74) Agent: AKHAVAN, Ramin; Caris Science, Inc., 6655 N . PCT/US20 12/0425 19 Macarthur Blvd., Irving, TX 75039 (US). (22) International Filing Date: (81) Designated States (unless otherwise indicated, for every 14 June 2012 (14.06.2012) kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, English (25) Filing Language: CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, Publication Language: English DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, (30) Priority Data: KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, 61/497,895 16 June 201 1 (16.06.201 1) US MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, 61/499,138 20 June 201 1 (20.06.201 1) US OM, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SC, SD, 61/501,680 27 June 201 1 (27.06.201 1) u s SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, 61/506,019 8 July 201 1(08.07.201 1) u s TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.
    [Show full text]
  • Coordinated Changes in Gene Expression, H1 Variant Distribution and Genome 3D Conformation in Response to H1 Depletion
    bioRxiv preprint doi: https://doi.org/10.1101/2021.02.12.429879; this version posted April 24, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission. Coordinated changes in gene expression, H1 variant distribution and genome 3D conformation in response to H1 depletion Núria Serna-Pujol1,#, Mónica Salinas-Pena1,#, Francesca Mugianesi2,#, François Le Dily3, Marc A. Marti-Renom2,3,4,5, Albert Jordan1,* 1Molecular Biology Institute oF Barcelona (IBMB-CSIC), Barcelona, 08028, Spain 2CNAG-CRG, Centre For Genomic Regulation, The Barcelona Institute oF Science and Technology, Baldiri Reixac 4, Barcelona, 08028, Spain 3Centre For Genomic Regulation, The Barcelona Institute For Science and Technology, Carrer del Doctor Aiguader 88, Barcelona, 08003, Spain 4Pompeu Fabra University, Doctor Aiguader 88, Barcelona, 08003, Spain 5ICREA, Pg. Lluís Companys 23, 08010 Barcelona, Spain # These authors contributed equally to this work. *To whom correspondence should be addressed. Tel: +34 93 402 0487; Fax: +34 93 403 4979; Email: [email protected] Running title: Consequences of H1 depletion on genome architecture 1 bioRxiv preprint doi: https://doi.org/10.1101/2021.02.12.429879; this version posted April 24, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission. Abstract Up to seven members oF the histone H1 Family may contribute to chromatin compaction and its regulation in human somatic cells. In breast cancer cells, knock-down of multiple H1 variants deregulates many genes, promotes the appearance oF genome-wide accessibility sites and triggers an interFeron response via activation oF heterochromatic repeats.
    [Show full text]
  • Identification of Biomarkers of Metastatic Disease in Uveal
    Identification of biomarkers of metastatic disease in uveal melanoma using proteomic analyses Thesis submitted in accordance with the requirements of the University of Liverpool for the degree of Doctor in Philosophy Martina Angi June 2015 To Mario, the wind beneath my wings 2 Acknowledgments First and foremost, I would like to acknowledge my primary supervisor, Prof. Sarah Coupland, for encouraging me to undergo a PhD and for supporting me in this long journey. I am truly grateful to Dr Helen Kalirai for being the person I could always turn to, for a word of advice on cell culture as much as on parenting skills. I would also like to acknowledge Prof. Bertil Damato for being an inspiration and a mentor; and Dr Sarah Lake and Dr Joseph Slupsky for their precious advice. I would like to thank Dawn, Haleh, Fidan and Fatima for becoming my family away from home, and the other members of the LOORG for the fruitful discussions and lovely cakes. I would like to acknowledge Prof. Heinrich Heimann and the clinical team at LOOC, especially Sisters Hebbar, Johnston, Hachuela and Kaye, for their admirable dedication to UM patients and for their invaluable support to clinical research. I would also like to thank the members of staff in St Paul’s theatre and Simon Biddolph and Anna Ikin in Pathology for their precious help in sample collection. I am grateful to Dr Rosalind Jenkins who guided my first steps in the mysterious word of proteomics, and to Dr Deb Simpsons and Prof. Rob Beynon for showing me its beauty.
    [Show full text]
  • Histopathologic, Genetic and Molecular Characterization of Endometrial Cancer Racial Disparity
    cancers Review Histopathologic, Genetic and Molecular Characterization of Endometrial Cancer Racial Disparity Pouya Javadian 1,* , Christina Washington 1, Shylet Mukasa 2 and Doris Mangiaracina Benbrook 1,* 1 Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, Stephenson Cancer Center, University of Oklahoma Health Sciences Center, Oklahoma City, OK 73104, USA; [email protected] 2 Arkansas College of Osteopathic Medicine, Fort Smith, AR 72916, USA; [email protected] * Correspondence: [email protected] (P.J.); [email protected] (D.M.B.) Simple Summary: Black patients are diagnosed and die earlier of endometrial cancer in comparison with their White counterparts. Factors that have been implicated in this racial disparity, such as socioeconomic status, increased frequencies of more aggressive tumor histology, and comorbid conditions, do not account for all of the disparity. Molecular defects in the endometrial tumors likely also contribute to the more aggressive tumor biology and the patient disparities. In this study, we reviewed the published data of molecular characteristics of endometrial cancer in different races. The majority of the publications compare Black and White patients, and identify molecules and pathways that can be targeted with existing drugs. These findings encourage molecular profile studies comparing additional races and ethnicities, and development of race-specific treatments. Abstract: In contrast to the decline in incidence and mortality of most other cancers, these
    [Show full text]
  • Global Proteomic Detection of Native, Stable, Soluble Human Protein Complexes
    GLOBAL PROTEOMIC DETECTION OF NATIVE, STABLE, SOLUBLE HUMAN PROTEIN COMPLEXES by Pierre Claver Havugimana A thesis submitted in conformity with the requirements for the degree of Doctor of Philosophy Graduate Department of Molecular Genetics University of Toronto © Copyright by Pierre Claver Havugimana 2012 Global Proteomic Detection of Native, Stable, Soluble Human Protein Complexes Pierre Claver Havugimana Doctor of Philosophy Graduate Department of Molecular Genetics University of Toronto 2012 Abstract Protein complexes are critical to virtually every biological process performed by living organisms. The cellular “interactome”, or set of physical protein-protein interactions, is of particular interest, but no comprehensive study of human multi-protein complexes has yet been reported. In this Thesis, I describe the development of a novel high-throughput profiling method, which I term Fractionomic Profiling-Mass Spectrometry (or FP-MS), in which biochemical fractionation using non-denaturing high performance liquid chromatography (HPLC), as an alternative to affinity purification (e.g. TAP tagging) or immuno-precipitation, is coupled with tandem mass spectrometry-based protein identification for the global detection of stably- associated protein complexes in mammalian cells or tissues. Using a cell culture model system, I document proof-of-principle experiments confirming the suitability of this method for monitoring large numbers of soluble, stable protein complexes from either crude protein extracts or enriched sub-cellular compartments. Next, I document how, using orthogonal functional genomics information generated in collaboration with computational biology groups as filters, we applied FP-MS co-fractionation profiling to construct a high-quality map of 622 predicted unique soluble human protein complexes that could be biochemically enriched from HeLa and HEK293 nuclear and cytoplasmic extracts.
    [Show full text]
  • Number 3 March 2012
    VolumeVolume 16 1 -- NumberNumber 31 May March- Sept ember2012 1997 Atlas of Genetics and Cytogenetics in Oncology and Haematology OPEN ACCESS JOURNAL AT INIST-CNRS Scope The Atlas of Genetics and Cytogenetics in Oncology and Haematology is a peer reviewed on-line journal in open access, devoted to genes, cytogenetics, and clinical entities in cancer, and cancer-prone diseases. It presents structured review articles ("cards") on genes, leukaemias, solid tumours, cancer-prone diseases, more traditional review articles on these and also on surrounding topics ("deep insights"), case reports in hematology, and educational items in the various related topics for students in Medicine and in Sciences. Editorial correspondance Jean-Loup Huret Genetics, Department of Medical Information, University Hospital F-86021 Poitiers, France tel +33 5 49 44 45 46 or +33 5 49 45 47 67 [email protected] or [email protected] Staff Mohammad Ahmad, Mélanie Arsaban, Marie-Christine Jacquemot-Perbal, Maureen Labarussias, Vanessa Le Berre, Anne Malo, Catherine Morel-Pair, Laurent Rassinoux, Alain Zasadzinski. Philippe Dessen is the Database Director, and Alain Bernheim the Chairman of the on-line version (Gustave Roussy Institute – Villejuif – France). The Atlas of Genetics and Cytogenetics in Oncology and Haematology (ISSN 1768-3262) is published 12 times a year by ARMGHM, a non profit organisation, and by the INstitute for Scientific and Technical Information of the French National Center for Scientific Research (INIST-CNRS) since 2008. The Atlas is hosted by INIST-CNRS (http://www.inist.fr) http://AtlasGeneticsOncology.org © ATLAS - ISSN 1768-3262 The PDF version of the Atlas of Genetics and Cytogenetics in Oncology and Haematology is a reissue of the original articles published in collaboration with the Institute for Scientific and Technical Information (INstitut de l’Information Scientifique et Technique - INIST) of the French National Center for Scientific Research (CNRS) on its electronic publishing platform I-Revues.
    [Show full text]
  • Blood Transcriptome Based Biomarkers for Human Circadian
    RESEARCH ARTICLE Blood transcriptome based biomarkers for human circadian phase Emma E Laing1*†, Carla S Mo¨ ller-Levet2†, Norman Poh3†, Nayantara Santhi4, Simon N Archer4, Derk-Jan Dijk4* 1Department of Microbial Sciences, School of Biosciences and Medicine, Faculty of Health and Medical Sciences, University of Surrey, Guildford, United Kingdom; 2Bioinformatics Core Facility, Faculty of Health and Medical Sciences, University of Surrey, Guildford, United Kingdom; 3Department of Computer Science, Faculty of Engineering and Physical Sciences, University of Surrey, Guildford, United Kingdom; 4Surrey Sleep Research Centre, School of Biosciences and Medicine, Faculty of Health and Medical Sciences, University of Surrey, Guildford, United Kingdom Abstract Diagnosis and treatment of circadian rhythm sleep-wake disorders both require assessment of circadian phase of the brain’s circadian pacemaker. The gold-standard univariate method is based on collection of a 24-hr time series of plasma melatonin, a suprachiasmatic nucleus-driven pineal hormone. We developed and validated a multivariate whole-blood mRNA- based predictor of melatonin phase which requires few samples. Transcriptome data were collected under normal, sleep-deprivation and abnormal sleep-timing conditions to assess robustness of the predictor. Partial least square regression (PLSR), applied to the transcriptome, *For correspondence: e.laing@ identified a set of 100 biomarkers primarily related to glucocorticoid signaling and immune surrey.ac.uk (EEL); d.j.dijk@surrey. function. Validation showed that PLSR-based predictors outperform published blood-derived 2 ac.uk (D-JD) circadian phase predictors. When given one sample as input, the R of predicted vs observed phase was 0.74, whereas for two samples taken 12 hr apart, R2 was 0.90.
    [Show full text]